Chunwan Lu
Overview
Explore the profile of Chunwan Lu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
1594
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Poschel D, Klement J, Merting A, Lu C, Zhao Y, Yang D, et al.
Cell Rep
. 2024 Oct;
43(10):114819.
PMID: 39368087
T cells function not only as an essential component of host cancer immunosurveillance but also as a regulator of colonic inflammation, a process that promotes colorectal cancer. Programmed death-ligand 1...
2.
Deng K, Liang L, Yang Y, Wu Y, Li Y, Zhang R, et al.
Int J Mol Sci
. 2024 Aug;
25(16).
PMID: 39201460
The WDR5/MLL1-H3K4me3 epigenetic axis is often activated in both tumor cells and tumor-infiltrating immune cells to drive various cellular responses in the tumor microenvironment and has been extensively studied in...
3.
Liang L, Yang Y, Deng K, Wu Y, Li Y, Bai L, et al.
Cells
. 2024 Jul;
13(13.
PMID: 38995014
PD-1 (Programmed cell death protein 1) regulates the metabolic reprogramming of myeloid-derived suppressor cells and myeloid cell differentiation, as well as the type I interferon (IFN-I) signaling pathway in myeloid...
4.
Yang Y, Bo S, Liang L, Deng K, Bai L, Wang T, et al.
ACS Nano
. 2024 Feb;
PMID: 38319978
Type I interferon (IFN-I) plays a critical role in host cancer immunosurveillance, but its expression is often impaired in the tumor microenvironment. We aimed at testing the hypothesis that cationic...
5.
Thakur A, Hu X, Zhao E, Lu C, Liu Y, Rustagi Y, et al.
Front Oncol
. 2023 Oct;
13:1286790.
PMID: 37810982
No abstract available.
6.
Klement J, Redd P, Lu C, Merting A, Poschel D, Yang D, et al.
Cancer Cell
. 2023 Mar;
41(3):620-636.e9.
PMID: 36917954
The cellular and molecular mechanisms underlying tumor cell PD-L1 (tPD-L1) function in tumor immune evasion are incompletely understood. We report here that tPD-L1 does not suppress cytotoxic T lymphocyte (CTL)...
7.
Yang Y, Zhang M, Zhang Y, Liu K, Lu C
Cancers (Basel)
. 2023 Mar;
15(5).
PMID: 36900354
Myelosuppression is a major adverse effect of 5-fluorouracil (5-FU) chemotherapy. However, recent findings indicate that 5-FU selectively suppresses myeloid-derived suppressor cells (MDSCs), to enhance antitumor immunity in tumor-bearing mice. 5-FU-mediated...
8.
Lu C, Yang D, Klement J, Colson Y, Oberlies N, Pearce C, et al.
Oncogene
. 2022 Mar;
41(18):2651-2662.
PMID: 35351997
The role of glucose-6-phosphate dehydrogenase (G6PD) in human cancer is incompletely understood. In a metabolite screening, we observed that inhibition of H3K9 methylation suppressed aerobic glycolysis and enhances the PPP...
9.
Merting A, Poschel D, Lu C, Klement J, Yang D, Li H, et al.
Cancers (Basel)
. 2022 Jan;
14(2).
PMID: 35053524
A hallmark of human colorectal cancer is lost expression of FAS, the death receptor for FASL of cytotoxic T lymphocytes (CTLs). However, it is unknown whether restoring FAS expression alone...
10.
Lu C, Yang D, Klement J, Colson Y, Oberlies N, Pearce C, et al.
J Immunother Cancer
. 2022 Jan;
10(1).
PMID: 35017152
Background: Granzyme B is a key effector of cytotoxic T lymphocytes (CTLs), and its expression level positively correlates with the response of patients with mesothelioma to immune checkpoint inhibitor immunotherapy....